The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
Open accessAbstract
PURPOSE: PROSTVAC, a viral vector–based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings. PATIENTS AND METHODS: Patients were randomly assigned to PROSTVAC (Arm V; n = 432), PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432), or placebo (Arm P; n = 433), stratified by prostate-specific antigen (less than 50 ng/mL v 50 ng/mL or more) and lactate dehydrogenase (less than 200 v 200 U/L or more). Primary end point was OS. Secondary end points were patients alive without events (AWE)—namely, radiographic progression, pain progression, chemotherapy initiation, or death—at 6 months and safety. The study design was a superiority trial of PROSTVAC (Arm V or Arm VG) versus Arm P. Three interim analyses were planned. RESULTS: At the third interim analysis, criteria for futility were met and the trial was stopped early. Neither active treatment had an effect on median OS (Arm V, 34.4 months; hazard ratio, 1.01; 95% CI, 0.84 to 1.20; P = .47; Arm VG, 33.2 months; hazard ratio, 1.02; 95% CI, 0.86 to 1.22; P = .59; Arm P, 34.3 months). Likewise, AWE at 6 months was similar (Arm V, 29.4%; odds ratio, 0.96; 95% CI, 0.71 to 1.29; Arm VG, 28.0%; odds ratio, 0.89; 95% CI, 0.66 to 1.20; placebo, 30.3%). Adverse events were similar for the treatment and placebo groups, with the most common being injection site reactions (62% to 72%) and fatigue (21% to 24%). Arrhythmias were the most common cardiac-related events (1.4% to 3.5%). There were no reports of either myocarditis or pericarditis. Serious treatment-related events occurred in less than 1% of all patients. CONCLUSION: Whereas PROSTVAC was safe and well tolerated, it had no effect on OS or AWE in metastatic castration-resistant prostate cancer. Combination therapy is currently being explored in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“Other treatment modalities for mCRPC that have demonstrated overall survival (OS) benefits include chemotherapy (docetaxel and cabazitaxel),(7-9) immunotherapy (sipuleucel-T),(10) and targeted a-therapy (radium-223).(11) PROSTVAC is an active immunotherapy vaccine that contains prostate-specific antigen (PSA) as the t…”
BackgroundSelf-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationFizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Self-citationRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citationBerthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Self-citation
Cited by
Sandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Cai, M., Song, X.-L., Li, X.-A., Chen, M., Guo, J., Yang, D.-H., Chen, Z., & Zhao, S.-C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100962 · Cited by 262
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Metadata
- Authors
- Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., Saad, F., Shore, N. D., Chen, L., Heery, C. R., Gerritsen, W. R., Priou, F., Langkilde, N. C., Novikov, A., & Kantoff, P. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-05-01
- Volume
- 37
- Issue
- 13
- Pages
- 1051-1061
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2915177933
- Cited by
- 285
- References
- 33
- FWCI
- 23.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.18.02031
- The paper
- Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., Saad, F., Shore, N. D., Chen, L., Heery, C. R., Gerritsen, W. R., Priou, F., Langkilde, N. C., Novikov, A., & Kantoff, P. W. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.02031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.